Document is current

Article History

Received: 28 January 2022

Accepted: 30 May 2022

First Online: 7 June 2022

Declarations

:

: The research was conducted in accordance with the Declaration of Helsinki. Ethical approval for the study was obtained from a National Research Ethics Committee (REC) and has been approved by the Independent Scientific Advisory Committee (ISAC) for Medicines and Healthcare products Regulatory Agency (MHRA) Database Research with protocol number 11_050AMnA2RA2. This work uses anonymised healthcare routinely collected data securely shared by GP practices across the UK and provided by Clinical Practice Research Datalink (CPRD). CPRD is a government organisation that obtain annual regulatory permission to supply anonymised data to researchers for approved public health studies and ensure that the supplied data are used to benefit public health and improve patient care. CPRD only receives and supplies anonymised patient data and complies with robust ethics, governance and security regulatory frameworks. The patient health data that CPRD holds have been processed in accordance with the Information Commissioner’s Office (ICO) Anonymisation Code of Practice. Individual patients have the right to opt out of their data being collected by CPRD for research.

: Not applicable.

: AJ reports grants from NIHR during the conduct of the study; personal fees from Freshfields Bruckhaus Derringer, personal fees from Anthera Pharmaceuticals Ltd, outside the submitted work; RGH reports grants from NIHR during the conduct of the study; RPV reports research funding from UK-NIHR, Kyowa Kirin Services, International Osteoporosis Foundation, and lecture fees and/or consulting honoraria from Amgen, UCB, Kyowa Kirin Services, and Mereo Biopharma, all outside of the scope of this study; VW reports grants from NIHR during the conduct of the study. All other authors declare no conflicts of interest.